- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07689669
Maternal Odor as a Developmental Care Intervention for Apnea of Prematurity (MOCARE)
PRETERM YENİDOĞANLARDA ANNE KOKUSUNUN APNE GELİŞİMİNE, FİZYOLOJİK PARAMETRELERE VE KİLO ALIMINA ETKİSİ
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Apnea of prematurity is a frequent complication of preterm birth and is associated with intermittent hypoxemia and adverse clinical outcomes. Developmental care interventions that provide familiar sensory stimulation may improve physiological stability in preterm infants. Maternal odor is a natural olfactory stimulus that may support autonomic regulation and respiratory stability through early sensory recognition.
This single-center, parallel-group, randomized controlled trial evaluated the effectiveness of maternal odor exposure in preterm infants admitted to the neonatal intensive care unit. Sixty eligible preterm infants were randomly assigned in a 1:1 ratio to either a maternal odor intervention group or a routine care control group. Maternal odor was provided using a cotton cloth impregnated with the mother's natural body odor, positioned approximately 10-15 cm from the infant's head for five consecutive days and replaced every 8 hours.
The primary outcome was the daily frequency of apnea episodes. Secondary outcomes included oxygen saturation (SpO₂), heart rate, respiratory rate, body temperature, weight, and head circumference. Outcomes were compared between groups to determine whether maternal odor exposure improves respiratory stability and physiological regulation in preterm infants.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Konya, Türkei (türkiye), 06370
- Selcuk University Faculty of Medicine Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Preterm infants born between 26 and 37 weeks of gestation
- Birth weight between 1000 and 2500 g
- Hospitalized in the neonatal intensive care unit for at least 5 days
- Receiving oral or enteral feeding
- Written informed consent obtained from parent(s) or legal guardian(s)
Exclusion Criteria:
- Endotracheal intubation, mechanical ventilation, or nasal continuous positive airway pressure
- Receiving oxygen therapy
- Congenital heart disease
- Suspected or confirmed sepsis
- Intracranial hemorrhage
- Receiving analgesic, sedative, or muscle relaxant therapy
- Previous surgical procedure
- Development of a medical condition requiring withdrawal from the study or hospitalization for less than 5 days
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Maternal odor group
Preterm infants received maternal odor exposure using a cotton cloth carrying the mother's natural body odor placed 10-15 cm from the infant's head for five consecutive days in addition to routine neonatal intensive care.
|
Maternal odor exposure was provided using a cotton cloth carrying the mother's natural body odor.
The cloth was placed approximately 10-15 cm from the infant's head during routine care for five consecutive days.
The cloth was replaced every 8 hours to maintain the maternal odor.
|
|
Kein Eingriff: Control group
Preterm infants received routine neonatal intensive cate without maternal odor exposure
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Frequency of Apnea Episodes
Zeitfenster: Daily for 5 consecutive days
|
Number of apnea episodes experienced by preterm infants during the 5-day study period.
Apnea episodes were recorded prospectively using the Premature Observation Form.
|
Daily for 5 consecutive days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Heart Rate
Zeitfenster: Measured four times daily for 5 consecutive days
|
Heart rate (beasts per minute) recorded during the study period and compared between the intervention and control groups
|
Measured four times daily for 5 consecutive days
|
|
Peripheral Oxygen Saturation
Zeitfenster: Measured four times daily for 5 consecutive days
|
Peripheral Oxygen Saturation (%) measured repeatedly during the study period and compared between the maternal odor and control groups.
|
Measured four times daily for 5 consecutive days
|
|
Respiratory Rate
Zeitfenster: Measured four times daily for 5 consecutive days
|
Respiratory rate (breaths per minute) recorded repeatedly during the study period and compared between the maternal odor and control groups.
|
Measured four times daily for 5 consecutive days
|
|
Body Temperature
Zeitfenster: Measured four times daily for 5 consecutive days
|
Body temperature recorded repeatedly during the study period and compared between the maternal odor and control groups.
|
Measured four times daily for 5 consecutive days
|
|
Weight Gain
Zeitfenster: Baseline and Day 5
|
Change in body weight (grams) from baseline to Day 5 and comparison between the maternal odor and control groups.
|
Baseline and Day 5
|
|
Head Circumference Growth
Zeitfenster: Baseline and Day 5
|
Change in head cincumference (cm) from baseline to Day 5 and comparison between the maternal odor and control groups.
|
Baseline and Day 5
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Geburtshilfe, Frühgeburt
- Geburtsbedingte Geburtskomplikationen
- Schwangerschaftskomplikationen
- Erkrankungen der Atemwege
- Atemstörungen
- Anzeichen und Symptome, Atmung
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Frühgeburt
- Apnoe
Andere Studien-ID-Nummern
- EKIZILER-002
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .